Background: Published trials of concurrent chemoradiotherapy (CCRT) in stage III non-
Introduction
The 5-year overall survival for patients presenting with stage III non-small-cell lung cancer (NSCLC) is poor, of clinically staged IIIA and IIIB NSCLC only 18% and 8%, respectively, and pathologically staged IIIA and IIIB disease between 25% and 19%, respectively [1] . The rates of locoregional failure are between 30% and 55%, with distant failure rates in the range of ≥50% [2] [3] [4] . Recent large phase III trials using carbo-or cisplatin-based combination chemotherapy achieved survival rates ranging from 12 to 22 months [2, 5, 6] . A metaanalysis by the NSCLC Collaborative Group evaluated the effect of either concurrent administration of chemotherapy and radiation (CCRT) or sequential chemotherapy and radiotherapy [7] and found improved overall survival for CCRT [hazard ratio (HR) = 0.84, 95% confidence interval (CI) 0.74-0.95, P = 0.004), with an absolute benefit of 5.7% (from 18.1% to 23.8%) at 3 years and 4.5% at 5 years. For progression-free survival, the HR was 0.90 (95% CI 0.79-1.01, P = 0.07). The survival benefits of CCRT were due to less locoregional progression (HR = 0.77, 95% CI 0.62-0.95, P = 0.01) as its effect on distant progression was not significantly different from that of sequential treatment (HR = 1.04, 95% CI 0.86-1.25, P = 0.69).
However, concerns about both toxicity and modest survival benefits have contributed to the slow implementation of CCRT in some European countries [8] . CCRT increases acute grade III/IV esophageal toxicity from 4% to 18% [7] , but esophagitis is largely reversible. The absence of a significant increase in radiation pneumonitis and late toxicity after CCRT was considered, in part, due to incompleteness of data. Another point of concern was the fact that patients included in the meta-analysis were not representative of the typical patients with this disease. For example, only 13% receiving CCRT were aged ≥70 years and 45% of patients included were <60 years [7] . A recent population-based analysis applied the inclusion criteria used for key phase III trials involving CCRT, as well as the ongoing phase III trial RTOG 0617/NCCTG N0628/CALGB 3060, and concluded that >50% of patients with stage III lung cancer in a Dutch population were 'theoretically ineligible' for CCRT [9] . Since 2003, we implemented a treatment approach for CCRT at our center for patients with stage III NSCLC treated outside clinical trials, which was based on (i) patients fitness to undergo treatment with systemic doses of cisplatin-based chemotherapy and (ii) use of radiation planning parameters predicting pulmonary toxicity to determine eligibility for high-dose radiotherapy (Figure 1) . Our approach was based on the fact that pulmonary oncologists had become much more experienced in safely administering cisplatin-based chemotherapy to patients with significant comorbidities, as well as elderly, during the last decade [10] . Furthermore, improved imaging and radiotherapy delivery techniques have enabled greater reductions in toxicity in recent times [11, 12] . Outcomes of this treatment paradigm are reported here.
Patients and methods

Treatment paradigm
CCRT using cisplatin-etoposide was implemented into routine care at our departments in 2003 , and details of all treated patients were entered into a prospective database. All patients were discussed within a multidisciplinary thoracic oncology workgroup before commencing treatment. However, (sequential) treatment policy for referred patients was often decided and initiated at the referring center. A performance status (PS) of zero, one or two was necessary to undergo systemic chemotherapy. Patients were eligible for CCRT when at least 46 Gy could be administered based on the INT 0139 phase III trial [5] , while respecting dose constraints to organs at risk, i.e. the percentage volume of lung tissue outside the planning target volume (PTV) receiving a threshold dose of ≥20 Gy was limited to 42% (V 20 ≤ 42%) (Figure 1 ) and the maximum spinal cord dose was limited to 50 Gy. If the patient had a V 20 between 36% and 42% and a mobile tumor on four-dimensional computed tomography (4D-CT) (motion of ≥7.5 mm), respiration-gated radiotherapy (RGRT), where the tumor is irradiated only in a selected phase of the respiratory cycle where it is relatively immobile, was used [13] . In patients in whom a preoperative 'downstaging' strategy was considered, effort was made to maximally spare the contralateral lung by minimizing the volume receiving a dose of 5 Gy (V 5 ). These 'potentially resectable' patients underwent surgery dependent on results of restaging procedures after induction CCRT. Patients were treated using sequential chemoradiotherapy or radiotherapy alone in case of refusal to accept CCRT, when the PS was poor and when V 20 >42%. Other (standard) treatment criteria as well as clinical and pathological staging were applied according to Dutch practice guidelines for NSCLC [14] . All patients had a whole-body fluoro Table 1) . During this period, doses of ≥50 Gy were not routinely administered to patients with bulky tumors and/or those with supraclavicular nodal metastases as the more conformal technique of intensity-modulated radiotherapy (IMRT) was not yet available at our center. Before the availability of IMRT, sequential chemoradiotherapy was preferred to CCRT in specified patient groups where high V 20 values were anticipated [15] . The latter included patients with metastases to the contralateral hilus, peripheral lower lobe tumors with contralateral upper mediastinal nodes and large retrocardiac tumors with mediastinal nodal metastases. After exclusion of patients treated with sequential chemoradiotherapy (n = 68), radiotherapy alone (n = 33) or other (n = 1), a total of 139 patients receiving CCRT (with the intention to administer at least 46 Gy in daily fractions of 2 Gy) were identified ( Table 1) . Of these patients, 50 had limited-volume, potentially operable N2 disease and underwent surgery, of which 24 have been described previously [16] . Consequently, the subjects of the present analysis are 89 stage III NSCLC patients who did not qualify for surgery due to reasons including extensive comorbidity, bulky disease, postsurgical recurrences and those with no downstaging after prior induction CCRT.
Comorbidity of all patients was scored using the Charlson comorbidity index (CCI) [17] , which in this study defines weighted number and seriousness of diseases next to NSCLC, without taking into account the age. In order to compare characteristics of our patients with published CCRT eligibility criteria used by De Ruysscher et al. [9] , we also applied the adapted CCI described in that article which classified selected diseases (other malignancies, hypertension, diabetes mellitus and some autoimmune diseases) as non-severe comorbidities. 
Details of radiotherapy planning
In order to permit the planning of image-guided involved-field radiotherapy (IFRT), treatment commenced with one cycle of induction chemotherapy and a 4D-CT scan was carried out for radiotherapy planning either before or during this first course. During 4D-CT scan, spatial and temporal information on organ mobility are generated while synchronously recording respiration waveforms. The tumor delineation encompassed all motion for patients not treated with RGRT. Treatment plans were generated using Eclipse version 8.1 (Varian Medical Systems, Palo Alto, CA) and generally consisted of two to six fields using 6 and/or 15 MV photons, with heterogeneity corrections. For the present analysis, all plans were recalculated using the analytical anisotropic algorithm, which allows for a more accurate calculation of the delivered dose [18] . Planning parameters for radiotherapy were derived from the dose-volume histograms of the original treatment plans. All initial treatment plans aimed to achieve International Commission on Radiation Units objectives by having the 95%
isodose volume (at a minimum) conformed as tightly as possible to the PTV, while respecting dose constraints to organs at risk as described earlier.
Chemo(radio)therapy schedules
Our 
Results
Patient characteristics
All 89 patients had pathologically proven NSCLC, and toxicity after 40 Gy (n = 1), disease progression after 14 Gy (n = 1), fatal lung bleeding after 6 Gy (n = 1) and the earlier mentioned fatal cerebrovascular event after 8 Gy. Overall, four patients (4.5%) died during treatment and six patients (6.7%) were not able to complete CCRT for reasons of toxicity and/or progression. Acute radiation esophagitis requiring tube feeding was observed in 25 patients (28.1%) but never exceeded this grade III. Esophagitis generally resolved soon after completion of CCRT; two patients had persistent dysphagia due to stenosis of the esophagus. One patient with a paraesophageal tumor developed a bronchoesophageal fistula, while no acute esophagitis was observed. Grade III radiation pneumonitis occurred in seven patients (7.9%), all of whom were hospitalized and treated with prednisolone. Higher grades of pneumonitis were not observed.
Radiotherapy planning results
Radiotherapy was delivered conventionally (3D) in 49 patients, and respiration-gated delivery was carried out in 40 patients (45%). Planning parameters of patients receiving a dose of <46 Gy (n = 4) were not evaluated. Three additional patients/treatment plans could not be evaluated due to calculation problems. Of the remaining 82, planning parameters are summarized in Table 3 .
Survival and statistical analysis
At the present analysis after an overall median follow-up of 16.8 months, 31 patients (34.8%)
were still alive with a median follow-up of 31.5 months. Overall median survival was No other categorical variables had a significant relation with survival. In this study, the presence or absence of comorbidities as scored by the method of De Ruysscher et al. [9] was not significantly different in terms of overall survival (P = 0.803) ( Figure 2D ). 
Discussion
Patients included in clinical trials do not reflect the overall stage III NSCLC population [9] . In particular, those with significant comorbidity and the elderly were underrepresented in previous clinical trials. As stage III NSCLC patients represent a heterogeneous population in terms of presentation and outcomes [19] , the selection criteria used for CCRT outside clinical trials are important.
Since 2003, our treatment paradigm in stage III disease has been based on two factors, namely the fitness to receive full-dose cisplatin-based chemotherapy and the radiation planning parameter V 20 . In our patient cohort, only 23% had a PS of 0, 28% were aged ≥70 years, 42% had one or more comorbidities and 14% had prior treatment of NSCLC. Nevertheless, a median overall survival of 18.2 months was achieved with modest toxicity. These findings compare favorably with an overall median survival of ~18 months reported in the latest meta-analysis on CCRT, encompassing six phase III studies with patient enrollment from 1988 to 2003 [7] . Our findings strongly argue for the use of less restrictive criteria concerning patient inclusion in routine practice of CCRT.
The suggestion that up to 59% of patients with stage III NSCLC are theoretically ineligible for CCRT based on inclusion criteria for previous and ongoing trials [9] is clearly inappropriate as this would have excluded at least 42% of our patients due to comorbidity. In particular, we observed no difference in survival of our patients with one or more important comorbidities versus those without comorbidity. Independent prognostic factors for overall survival on multivariate analysis were PS and the PTV.
Some aspects of our results merit further comment. A higher median survival of 21.7 months was reported in a recent phase III trial (HOG-LUN 01-24) investigating cisplatinbased CCRT with or without consolidation docetaxel [6] . However, patients in our report represent a less fit subgroup with more extensive tumors as CCRT followed by resection had been our policy for patients with limited-volume stage III disease who were treated during the same period [16] . Despite the comorbidities, our treatment dropout rate of 11.2% compares favorably with a 20%-23% incidence reported in the recent literature [5, 20] . It should be noted that our patients routinely underwent staging FDG-PET scans and IFRT based on 4D-CT scans. The relatively low median radiotherapy dose of 59.5 Gy to the PTV (range 44.3-69.2 Gy) reflects the fact that we did not have access to the technique of IMRT during the period in question. At present, most of the patients in this category receive a minimum dose of 60 Gy with the use of IMRT approaches. Acute radiation esophagitis continues to be an important cause of morbidity with CCRT, and despite our use of IFRT, a grade III esophagitis occurred in 23.8% of patients. However, no grade IV toxicity was seen and late toxicity is uncommon. Incidence of esophagitis grade III or higher in other recent phase III trials ranges from 23% [5] to 34% [2] .
Despite including patients with a V 20 of up to 39.4%, grade III or higher pneumonitis was observed in only 8% of our cohort. Although earlier recommendations had suggested caution when using CCRT in patients with V 20 values >35% [11] , more recent prospective data led to our acceptance of a V 20 of 36%-42%. Grade II-V radiation pneumonitis was only observed in 7% of patients in the HOG-LUN 01-24 study [21] , despite V 20 values ranging from 5% to 74% (median 35%). Similarly, the phase III SWOG 0023 trial reported grade III or higher pneumonitis in only 10% of patients with V 20 >35% [22] .
Another potential option to allow safe implementation of CCRT is individualizing radiation doses based on normal tissue dose constraints [23] . Van Baardwijk et al. [24] recently reported on a prospective study with sequential chemoradiotherapy in NSCLC using these 'biologically optimized' radiotherapy doses (hyperfractionated) up to 79.2 Gy. Median survival rates in this study were only 16.2 months for stage IIIA and 17.2 months for stage IIIB disease. These authors reported acceptable acute and late toxicity; mean lung dose was 19 Gy compared with 15.8 Gy in our study. Only 55% of patients treated with this sequential 'biologically optimized' radiotherapy received induction chemotherapy, and the 67% incidence of distant disease as the first site of recurrence emphasizes the need for incorporating adequate systemic doses of chemotherapy. Another example is the EORTC 08972 study of Belderbos et al. [4] , where daily low-dose cisplatin (6 mg/m 2 ) was administered concurrent with radiotherapy to 66 Gy and where the median survival was only 16.5 months. The use of daily low-dose cisplatin has not been shown to influence systemic relapses [25] .
Nearly 20% of our patients developed brain metastases, with most being diagnosed within 1 year after start of treatment. The high incidence and early manifestation of brain metastases in stage III NSCLC is well recognized and we now follow the recommendation for routine pretreatment brain imaging (CT/magnetic resonance imaging) before CCRT [26] . The retrospective nature of our analysis is a limitation but the follow-up of our patients for both toxicity and progression was nearly complete. The very fact that these patients were either ineligible or had declined participation in studies suggests that our conclusions are a better reflection of CCRT outcomes in the community. We report that both PS ≥1 and high PTV had a significantly negative impact on survival. However, new radiotherapy techniques are available now (including IMRT) that can potentially increase local control rate [27] , especially for large tumors, but this will have to be validated in prospective randomized trials.
In conclusion, our data indicate that concerns about comorbidities should not be a reason for not applying CCRT in patients with a PS of zero or one, who are otherwise fit to receive systemic doses of chemotherapy. IIIB  IIIA  IIIB  IIIA  IIIB  IIIA  IIIA  IIIB  IIIA  IIIA  IIIB  IIIB   Clinical  TNM  T4N2M0  T2N2M0  T4N0M0  T1N2M0  T4NxM0  TxN2M0  TxN2M0  TxN3M0  TxN2M0  TxN2M0  TxN3M0  TxN3M0 Site 
